Skip to content

Kengrexal 50 mg powder for concentrate for solution for injection/infusion

DRUG3 trials

Sponsors

Azienda Ospedaliero-Universitaria Maggiore Della Carita, Ospedale San Raffaele S.r.l., Fondation A De Rothschild

Conditions

Acute ischemic strokeAdult patients treated in VA ECMO/Impella for cardiogenic shock/cardiac arrest undergoing PCI. Given the high incidence of bleeding from conventional antithrombotic therapyST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)the use of readily available and rapidly metabolized cangrelor should result in adequate efficacy and increased safety. Patients will receive scoagulation with bivalirudin (target apt 55-70 seconds) and cangrelor with starting dose 0.125 mcg/kg/min and adjusted with step +/- 0.125 mcg/kg/min.

Phase 2

Phase 3

Phase 4